Posts

The clinical and pathological significance of increased expression of the cannabinoid receptors CB-1R and CB-2R in patients with papillary thyroid carcinomas compared to benign thyroid lesions

Phytocannabinoids have been shown to inhibit the aggregation and neurotoxicity of the neurotoxic Alzheimer’s disease protein beta amyloid (Aβ). We characterised the capacity of six phytocannabinoids: cannabichromene, cannabigerol, cannabinol, cannabidivarin, cannabidiol and Δ9-tetrahydrocannabinol, to disrupt Aβ aggregation and protect against Aβ-evoked neurotoxicity in PC12 cells. Neuroprotection against lipid peroxidation and Aβ-induced cytotoxicity was assessed using the MTT assay. Transmission electron microscopy was used to visualise phytocannabinoid effects on Aβ aggregation and fluorescence microscopy, with morphometrics and principal component analysis to assess PC12 cell morphology.

Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract.

Authors: Giorgia Galiazzo, Fiorella Giancola, Agnese Stanzani, Federico Fracassi, Chiara Bernardini, Monica Forni, Marco Pietra, Roberto Chiocchetti
Histochemistry and Cell Biology, August 2018

The endocannabinoid system (ECS) is composed of cannabinoid receptors, their endogenous ligands, and the enzymes involved in endocannabinoid turnover. Modulating the activity of the ECS may influence a variety of physiological and pathophysiological processes. A growing body o…

Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system.

Authors: Jessica Freundt-Revilla, Kristel Kegler, Wolfgang Baumgärtner, Andrea Tipold
PLoS One, 10 July 2017

The endocannabinoid system is a regulatory pathway consisting of two main types of cannabinoid receptors (CB1 and CB2) and their endogenous ligands, the endocannabinoids. The CB1 receptor is highly expressed in the central and peripheral nervous systems (PNS) in mammalians and…

Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.

Authors: Eduardo Pérez-Gómez, Clara Andradas, Sandra Blasco-Benito, María M. Caffarel, et al
Journal of the National Cancer Institute, 8 April 2015

BACKGROUND: Pharmacological activation of cannabinoid receptors elicits antitumoral responses in different cancer models. However, the biological role of these receptors in tumor physio-pathology is still unknown. METHODS: We analyzed CB2 cannabinoid receptor protein expressio…

Primary gliosarcoma of the brain: radiologic and histopathologic features.

Authors: Alfredo E. Romero-Rojas, Julio A. Diaz-Perez, Lina M. Ariza-Serrano, et al
The Neuroradiology Journal, December 2013

Gliosarcoma is a rare central nervous system (CNS) neoplasm with biphasic glial and non-glial malignant components. Here we describe the radiologic and histopathologic features observed in five cases of primary gliosarcoma. The mean age at diagnosis in the studied patients was…

Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis.

Authors: Luca Campora, Vincenzo Miragliotta, Emanuele Ricci, Luigia Cristino, Vincenzo Di Marzo, et al
American Journal of Veterinary Research, July 2012

OBJECTIVE: To determine the distribution of cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2) in skin (including hair follicles and sweat and sebaceous glands) of clinically normal dogs and dogs with atopic dermatitis (AD) and to compare results with thos…

Endocannabinoid involvement in endometriosis.

Authors: Natalia Dmitrieva, Hiroshi Nagabukuro, David Resuehr, Guohua Zhang, Stacy McAllister, et al
Pain, December 2010

Endometriosis is a disease common in women that is defined by abnormal extrauteral growths of uterine endometrial tissue and associated with severe pain. Partly because how the abnormal growths become associated with pain is poorly understood, the pain is difficult to alleviat…